

April 24, 2013

Memorandum

To: Michael Maddux -ACCP
Thomas E. Menighan – APhA
Paul Abramowitz - ASHP
Debra S. BenAvram - ASPEN
Brenda Schimenti - CPNP
Karen Nason - HOPA
Matthew R. Helms - PPAG

From: Joseph Saseen
2013 BPS Chair

William Ellis
BPS Executive Director

RE: BPS Strategic Plan

BPS was very pleased to recently announce the approval of two new specialties; one in critical care pharmacy the other in pediatric pharmacy. The petition review process for these two specialties involved a very good dialogue with the petitioning organizations. As a result of this dialogue and consistent with the BPS Strategic Planning White Paper, the BPS Board has agreed to proceed by creating a scalable foundational model for the future board certification of pharmacists. The Board hopes to complete an evaluation process within the next twelve months. It is envisioned that stakeholders will be convened to gather input on relevant items related to this future model at a date to be determined later this year.

The BPS Board anticipates:

- Discussing and potentially revising the overall petition submission process to recognize pharmacy specialties
- Exploring a potential subspecialties recognition model (that would replace the current Added Qualifications program)

BPS realizes that this evaluation process, as stated in the white paper, “must occur in a way that accommodates and encourages the evolutionary growth of pharmacist board certification through flexibility and efficiency for all stakeholders. However, remaining steadfast to the rigor and quality of the BPS process and the accreditation standards established by the National Commission for Certifying Agencies will be essential.

BPS further believes that the future growth of pharmacist board certification should progress in a manner consistent with the Council on Credentialing in Pharmacy Framework for Credentialing in Pharmacy Practice, which illustrates the continuum of a pharmacist’s career from professional education to board certification. BPS supports this framework as particularly valuable because the role of the pharmacist is continuing to evolve and this model accommodates that evolution.”

Considering the important nature of these discussion items, and the significant investment that BPS has made in role delineation studies, the Board believes the review of current role delineation studies in cardiology and infectious diseases and the consideration of new specialties should be finalized at the conclusion of the future board certification model discussion. BPS looks forward to sharing more information with you in the months ahead and to your participation in the process.